Taragenyx announces expansion of granted patent portfolio
- Glasgow biotech secures USA patent protection for self-healing implant technologies -
Orthopaedic biotechnology company, Taragenyx Ltd., announced
today the expansion of its granted patent portfolio in both the European Union and in the USA.
Following from the grant of European Patent 2435602 in May this year, the US Patent and Trade Mark Office (USPTO) has now notified Taragenyx of its intent to grant a patent from its U.S. Patent Application No. 13/322,226. This patent grant expands the Taragenyx intellectual property estate for its core technologies in therapeutic implant coatings.
The Coating Method developed by Taragenyx is a significant advance in orthopaedic medical implant design, providing accurate release of therapeutic drug compounds while fitting seamlessly within existing manufacturing and production processes. The method uses hybrid-coating particles that can be sprayed onto the surface of an implant using existing thermal spray processes. In addition the hybrid particles can also be 3D printed to form novel custom structures, or compounded into base implant biomaterials. Presence of these hybrid particles produces a highly osteo-conductive surface which gives rise to accelerated osseo-integration and stronger anchoring to host bone tissues, thus reducing the healing time required prior to loading of the implant.
Iain McDougall, CEO of Taragenyx stated that “the continued expansion of our granted patent portfolio in both of the company’s main customer markets of Europe and USA demonstrates the unique position of the company’s technology and confirms the development strategy being pursued by the company in bringing novel therapeutic implant coatings to market. “
Taragenyx has pioneered the development of self-healing therapeutic implants aimed at tackling the incredibly painful and expensive problem of orthopaedic implant failure.
Taragenyx are backed by Kelvin Capital, Lancaster Capital, and the Scottish Investment Bank, with offices in Entrepreneurial Spark and laboratory facilities within the University of Glasgow. The company is the youngest and only biotech company on the prestigious London Stock Exchange ELITE Program for high growth businesses.